An Interesting Combination Is Under Investigation
Most headlines about obesity research focus on completed studies.
But sometimes the most interesting question appears earlier, when researchers register a new trial.
Macupatide and eloralintide are the subject of such a study.
The public registry describes a Phase 2 study of the two compounds, alone and together, in adults with obesity or overweight and type 2 diabetes. [1]
The registration provides information about the study’s design and planned outcomes.
It does not provide the answers.
What Is Registered?
The study is identified as NCT07215559.
Its registered title is:
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes. [1]
The full registry title describes it as a Phase 2, parallel-group, double-blind, placebo-controlled study. [1] Eli Lilly and Company is the sponsor. [1]
The research is designed to investigate weight reduction under different treatment assignments.
That includes evaluation of the individual compounds and their combination.
Trial Phase and Population
ClinicalTrials.gov lists the study as Phase 2. [1]
Its population comprises adults aged 18 to 75 with type 2 diabetes, an HbA1c between 7.5% and 10.5% at screening, and a BMI of 27 or higher. [1]
Participants must have been treated with diet and exercise, a stable dose of metformin or an SGLT2 inhibitor, alone or in combination, for at least three months. The record excludes people who recently used GLP-1 receptor agonists, GIP/GLP-1 receptor agonists, amylin agonists or insulin. [1]
That population matters because metabolic characteristics and background treatment conditions can influence trial design and interpretation.
The presence of type 2 diabetes distinguishes it from some earlier obesity studies that excluded that diagnosis.
Enrollment and Recruitment
As of October 12, 2026, the registry lists a planned enrollment of 200 participants. [1]
The registry lists the recruitment status as active, not recruiting. That means the study is ongoing but no longer enrolling new participants. [1] Participation lasts about 48 weeks. [1]
The record lists sites in the United States, Argentina, Australia and Puerto Rico. [1]
These are administrative details that may change as research progresses.
A study’s recruiting status is not a report of efficacy or safety.
What Is the Primary Outcome?
The registered primary outcome is Percent Change from Baseline in Body Weight, measured from baseline to Week 32. [1]
The registry lists three secondary outcomes, each also measured from baseline to Week 32: change in hemoglobin A1c, change in body mass index, and change in fasting glucose. [1]
These are measurements researchers intend to collect.
They are not posted results. The registry shows no results for this study. [1]
When Is the Study Expected to Finish?
The registry lists a start date of October 16, 2025, a primary completion date of March 2027 and a study completion date of May 2027. [1]
Expected dates can change.
They should be described as current registry estimates, not guaranteed completion dates.
What Can We Conclude From Registration?
We can conclude that the research program exists and has a documented plan.
The public information shows the study’s stated population, intended comparisons and planned outcome measurements.
It does not show that the combination produces a particular weight reduction.
It does not determine the relative tolerability of the compounds.
And it cannot predict whether the study will meet its primary endpoint.
Is There Another Registered Study?
Yes. A search of the registry on October 12, 2026 found related Lilly records involving the same two compounds. They are different studies and should not be merged with NCT07215559.
NCT07589608 is a Phase 2b study of macupatide and eloralintide, alone or in combination, in adults with obesity or overweight and without type 2 diabetes. [2] The registry lists 400 planned participants, a recruiting status, a start date of May 15, 2026 and a primary outcome of percent change in body weight at Week 36. [2] It runs under the master protocol NCT06143956. [2][3]
NCT07765511 is a Phase 1 multiple-dose study in Japanese participants with obesity or overweight without type 2 diabetes. It evaluates macupatide alone and with eloralintide, with 60 planned participants. The registry lists it as not yet recruiting, with a primary outcome focused on serious adverse events. [4]
NCT06143956 is the master protocol, a Phase 2 framework that allows several investigational interventions to be tested under shared entry criteria. [3]
None of these records reports results.
The Bottom Line
NCT07215559 is a registered Phase 2 study investigating macupatide and eloralintide alone and in combination in adults with type 2 diabetes.
The registry tells us what the investigators intend to measure.
The eventual evidence will come from study results, not from the registration itself.
That distinction is the entire point of following research carefully.
Frequently Asked Questions
What is the trial identifier?
NCT07215559. [1]
What is the study phase?
ClinicalTrials.gov lists it as Phase 2. [1]
What is the primary research question?
The study investigates weight reduction with macupatide and eloralintide alone or in combination in adults with obesity or overweight and type 2 diabetes. [1]
Does the registration show that the combination works?
No. A trial registration is a description of planned research, not evidence of successful outcomes.
Further reading: The NCT07215559 trial record, Clinical development and Eloralintide sequence and structure
Editorial note
This article discusses investigational drug research for educational purposes. It does not provide medical advice, treatment recommendations, or instructions for obtaining or administering experimental compounds. Clinical findings should be interpreted within their original study populations and methodological limitations.